CONMED Corporation (CNMD) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.4B	1.4B	1.3B	1.2B	1.0B
Cost of Revenue	620.4M	649.1M	574.0M	568.5M	474.2M
Gross Profit	752.2M	725.4M	733.0M	676.2M	571.2M
Operating Expenses
R&D Expense	60.6M	55.9M	54.4M	52.6M	47.2M
SG&A Expense	543.5M	528.4M	478.3M	503.0M	454.0M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	604.1M	584.2M	532.7M	555.6M	501.2M
Cost and Expenses	1.2B	1.2B	1.1B	1.1B	975.4M
Operating Income (EBIT)	148.1M	141.1M	200.3M	120.6M	70.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	29.9M	31.1M	37.3M	39.8M	28.9M
Net Interest Income	(29.9M)	(31.1M)	(37.3M)	(39.8M)	(28.9M)
Other Non-Op Income/Expense	(64.9M)	(70.0M)	(37.3M)	(39.8M)	(140.9M)
Non-Operating Income (excl Interest)	34.9M	38.9M	—	—	112.0M
EBT (Pre-Tax Income)	83.2M	71.1M	163.0M	80.8M	(70.9M)
Income Tax Expense	26.7M	24.1M	30.6M	16.4M	9.7M
Bottom Line
Net Income	56.5M	47.1M	132.4M	64.5M	(80.6M)
Earnings from Cont. Ops	56.5M	47.1M	132.4M	64.5M	(80.6M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	56.5M	47.1M	132.4M	64.5M	(80.6M)
Per Share
Basic EPS	$1.85	$1.52	$4.29	$2.10	($2.68)
Diluted EPS	$1.85	$1.51	$4.26	$2.04	($2.68)
Revenue Per Share	$45.65	$44.29	$42.37	$40.59	$34.80
Shares
Basic Shares Outstanding	30.1M	31.0M	30.8M	30.7M	30.0M
Diluted Shares Outstanding	30.1M	31.1M	31.1M	31.5M	30.0M
Profitability Metrics
EBITDA	180.0M	154.5M	272.2M	192.5M	7.8M
D&A	66.8M	52.3M	71.9M	71.9M	49.8M
EBIT	113.1M	102.2M	200.3M	120.6M	(42.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026